Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11544557 | 0.83 | MAPT (0.59) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL30881082 | 0.82 | MAT2A (0.55) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL27388953 | 0.82 | MAT2A (0.55) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL4194781 | 0.81 | POLB (0.43) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL4190441 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL7433737 | 0.79 | HTR3E (0.54) | ALDH1A1KDM4EKMT2AMEN1MAPT | |
| SCHEMBL378029 | 0.79 | KDM4E (0.61) | ALDH1A1KDM4EKMT2AMEN1ATM | |
| SCHEMBL2409501 | 0.76 | FEN1 (0.57) | ALDH1A1KMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL11469525 | 0.76 | KDR (0.47) | ALDH1A1KDM4EKMT2AATML3MBTL1 | |
| SCHEMBL6998519 | 0.76 | KDR (0.47) | ALDH1A1KDM4EKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8193356-B2 | Heterocycle compound, and production process and application thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1925617-A1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-5382572-A | Viricides | SCHERING CORPORATION (US) | 1995-01-17 | — | — | US | disclosed |
| US-5378694-A | Herpes viricide, hypotensive agent | SCHERING CORPORATION (US) | 1995-01-03 | — | — | US | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0550464-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1993-07-14 | — | — | EP | disclosed |
| EP-0547145-A1 | ANTIVIRAL 2(1H)-QUINOLINONE COMPOUNDS | SCHERING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| US-5190956-A | Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections | SCHERING CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5179093-A | Viricides | SCHERING CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| US-5179107-A | Herpes | SCHERING CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| WO-1992004328-A1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004326-A1 | ANTIVIRAL COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| US-3968119-A | OPTICAL BRIGHTENERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | PDE3B, PDE4B, PDE7A | ALDH1A1 1422/4885KDM4E 426/4885KMT2A 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.